At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 107 enrolled
Drug / intervention
Adalimumab +1 morebiological
Likely dose
Adalimumab 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Multicenter Placebo-controlled Trial on the Effect of Adalumumab on Vascular Inflammation in Patient With Moderate to Severe Psoriasis
In Brief
A Phase 4 clinical trial evaluating Adalimumab and Placebo for Psoriasis and 2 related conditions. Completed, enrolled 107 participants across 5 sites.
Detailed Summary
This study is a double-blinded randomized multicenter placebo controlled trial to determine the effect of adalimumab on vascular inflammation (ascending aorta and carotides) in patients with moderate to severe psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis, Vascular Inflammation, Coronary Atherosclerosis
CountriesCanada
CollaboratorsAbbott, Montreal Heart Institute
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2012
First PostedNov 2012
Primary CompletionDec 2015
Study CompletionJan 2016
TodayJul 2026
First PostedNov 6, 2012
Enrollment StartNov 1, 2012
Primary CompletionDec 1, 2015
Study CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 13.7 years ago
Interventions
Adalimumabbiological
Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 52 weeks). For Adalimibab group and Placebo group.
Placeboother
Injection of placebo that is physicaly identical to adalimumab without the active ingredient at identical intervals.